STAR Q1 FY27 results at a glance
STRIDES PHARMA SCI LTD Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹1,265 cr |
|---|
| Revenue YoY | +13.0% |
|---|
| Operating profit | ₹173 cr |
|---|
| Operating margin | 13.7% |
|---|
| Net profit | ₹157 cr |
|---|
| Net profit YoY | +57.5% |
|---|
| Net profit QoQ | +23.6% |
|---|
| Net margin | 12.4% |
|---|
| Basic EPS | ₹17.02 |
|---|
| TTM revenue | ₹4,903 cr |
|---|
| TTM net profit | ₹586 cr |
|---|
| TTM net margin | 11.9% |
|---|
STAR Q1 FY27 results: what the numbers say
STRIDES PHARMA SCI LTD (STAR) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹1,265 cr and a net profit of ₹157 cr, translating into earnings per share of ₹17.02.
Compared with the same quarter a year earlier, revenue grew by +13.0% and net profit grew sharply by +57.5%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹173 cr, an operating margin of 13.7% versus 15.1% a year ago — a contraction of 1.4 percentage points.
STAR quarter-wise results table
Revenue
₹1,265 cr
+13.0% YoY
Net profit
₹157 cr
+57.5% YoY
Operating profit
₹173 cr
+2.5% YoY
STRIDES PHARMA SCI LTD (STAR) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹1,265 cr | ₹173 cr | ₹157 cr | 13.7% | 12.4% | ₹17.02 | +57.5% | +23.6% |
| Q4 FY262026-03-31 | ₹1,323 cr | ₹186 cr | ₹127 cr | 14.1% | 9.6% | ₹13.77 | +54.4% | -37.2% |
| Q3 FY262025-12-31 | ₹1,195 cr | ₹185 cr | ₹202 cr | 15.5% | 16.9% | ₹21.93 | — | +102.9% |
| Q1 FY262025-06-30 | ₹1,120 cr | ₹169 cr | ₹99.61 cr | 15.1% | 8.9% | ₹10.81 | — | +21.2% |
| Q4 FY252025-03-31 | ₹1,190 cr | ₹169 cr | ₹82.19 cr | 14.2% | 6.9% | ₹8.92 | — | — |
| TTM (last 4 quarters) | ₹4,903 cr | ₹714 cr | ₹586 cr | 14.6% | 11.9% | ₹63.53 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
STAR quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
STRIDES PHARMA SCI LTD quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q1 FY262025-06-30 | Q4 FY252025-03-31 |
|---|
| Revenue / Sales | ₹1,265 cr | ₹1,323 cr | ₹1,195 cr | ₹1,120 cr | ₹1,190 cr |
|---|
| Total expenses | ₹1,092 cr | ₹1,137 cr | ₹1,009 cr | ₹951 cr | ₹1,021 cr |
|---|
| Gross profit | ₹770 cr | ₹787 cr | ₹732 cr | ₹675 cr | ₹691 cr |
|---|
| Operating profit (EBIT) | ₹173 cr | ₹186 cr | ₹185 cr | ₹169 cr | ₹169 cr |
|---|
| Operating margin | 13.7% | 14.1% | 15.5% | 15.1% | 14.2% |
|---|
| Interest cost | ₹40.56 cr | ₹41.58 cr | ₹43.38 cr | ₹47.46 cr | ₹50.32 cr |
|---|
| Profit before tax | ₹200 cr | ₹148 cr | ₹245 cr | ₹122 cr | ₹106 cr |
|---|
| Tax expense | ₹34.12 cr | ₹18.77 cr | ₹37.35 cr | ₹16.45 cr | ₹20.76 cr |
|---|
| Effective tax rate | 17.1% | 12.7% | 15.2% | 13.5% | 19.5% |
|---|
| Net profit (PAT) | ₹157 cr | ₹127 cr | ₹202 cr | ₹99.61 cr | ₹82.19 cr |
|---|
| Net profit margin | 12.4% | 9.6% | 16.9% | 8.9% | 6.9% |
|---|
| Basic EPS | ₹17.02 | ₹13.77 | ₹21.93 | ₹10.81 | ₹8.92 |
|---|
| Diluted EPS | ₹17.02 | ₹13.77 | ₹21.92 | ₹10.81 | ₹8.92 |
|---|
STAR results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q1 FY26 | Q4 FY25 |
|---|
| Revenue YoY | +13.0% | +11.2% | — | — | — |
|---|
| Revenue QoQ | -4.4% | +10.8% | +6.7% | -5.9% | — |
|---|
| Operating profit YoY | +2.5% | +10.3% | — | — | — |
|---|
| Operating profit QoQ | -7.0% | +0.6% | +9.5% | +0.1% | — |
|---|
| Net profit YoY | +57.5% | +54.4% | — | — | — |
|---|
| Net profit QoQ | +23.6% | -37.2% | +102.9% | +21.2% | — |
|---|
| EPS YoY | +57.4% | +54.4% | — | — | — |
|---|
| EPS QoQ | +23.6% | -37.2% | +102.9% | +21.2% | — |
|---|
STAR annual results history
Full-year performance for STRIDES PHARMA SCI LTD, useful for reading each quarter in context.
STRIDES PHARMA SCI LTD annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹4,628 cr | ₹4,392 cr | ₹3,730 cr | ₹3,608 cr |
|---|
| Total expenses | ₹4,011 cr | ₹3,812 cr | ₹3,409 cr | ₹3,465 cr |
|---|
| Gross profit | ₹2,461 cr | ₹2,258 cr | ₹1,846 cr | ₹1,862 cr |
|---|
| Operating profit (EBIT) | ₹617 cr | ₹580 cr | ₹321 cr | ₹143 cr |
|---|
| Operating margin | 13.3% | 13.2% | 8.6% | 4.0% |
|---|
| Interest cost | ₹150 cr | ₹207 cr | ₹239 cr | ₹218 cr |
|---|
| Profit before tax | ₹669 cr | ₹487 cr | -₹115 cr | -₹286 cr |
|---|
| Tax expense | ₹94.17 cr | ₹77.52 cr | ₹29.11 cr | -₹55.3 cr |
|---|
| Effective tax rate | 14.1% | 15.9% | -25.4% | 19.3% |
|---|
| Net profit (PAT) | ₹556 cr | ₹3,593 cr | -₹70.61 cr | -₹203 cr |
|---|
| Net profit margin | 12.0% | 81.8% | -1.9% | -5.6% |
|---|
| Basic EPS | ₹60.34 | ₹390.55 | ₹-7.76 | ₹-22.49 |
|---|
| Diluted EPS | ₹60.34 | ₹390.50 | ₹-7.76 | ₹-22.49 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹1,265 cr against ₹1,120 cr in Q1 FY26, and ₹1,323 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue declined -4.4%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹1,092 cr, or 86.3% of revenue, with operating profit grew +2.5% year on year.
Margins, tax and profitability
Net profit of ₹157 cr works out to a net margin of 12.4% compared with 8.9% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, STRIDES PHARMA SCI LTD reported profit before tax of ₹200 cr, a tax charge of ₹34.12 cr (effective rate 17.1%), interest cost of ₹40.56 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹127 cr in Q4 FY26 to ₹157 cr in Q1 FY27, a change of +23.6%.
Trailing twelve months and annual context
Across the trailing four quarters STRIDES PHARMA SCI LTD has generated revenue of ₹4,903 cr and net profit of ₹586 cr, a trailing net margin of 11.9%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹4,628 cr with net profit of ₹556 cr and EPS of ₹60.34, versus the prior year where revenue grew +5.4% and profit declined -84.5%.
What to watch in the next STAR quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
STRIDES PHARMA SCI LTD has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
STAR results coverage
No results report published for STAR yet — our desk covers each quarter within minutes of the filing.
STAR quarterly results FAQs
What were STRIDES PHARMA SCI LTD (STAR) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), STRIDES PHARMA SCI LTD reported revenue of ₹1,265 cr and net profit of ₹157 cr, a change of +57.5% year on year on +13.0% revenue growth. EPS stood at ₹17.02.
What is STAR profit margin in Q1 FY27?
STRIDES PHARMA SCI LTD posted a net profit margin of 12.4% and an operating margin of 13.7% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹4,903 cr and net profit ₹586 cr.
Did STAR results beat the previous quarter?
STRIDES PHARMA SCI LTD net profit changed +23.6% quarter on quarter, from ₹127 cr in Q4 FY26 to ₹157 cr in Q1 FY27.
When are STRIDES PHARMA SCI LTD (STAR) quarterly results?
STRIDES PHARMA SCI LTD has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see STAR latest quarterly results?
Results coverage for STAR will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the STAR stock page.
What is STRIDES PHARMA SCI LTD annual revenue and profit?
For FY26, STRIDES PHARMA SCI LTD reported full-year revenue of ₹4,628 cr and net profit of ₹556 cr, with EPS of ₹60.34.
How many quarterly results has STAR declared recently?
Past results dates for STAR will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 11 Sept 2026. For information only, not investment advice.
